Clinical trialPhase 2Terminated
Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
TRIPPLE-R: Phase 2 Study in Pretreated Patients With Advanced Pancreatic Cancer to Assess Efficacy of Ipilimumab, Nivolumab and Tocilizumab in Combination With Radiation
- Outcome
- Stopped earlyprimary endpoint was not met (Efficacy or futility)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 16 April 2020
- Expected end
- 23 November 2021
- Enrollment
- 26 participants
- Sites
- 1
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- Other
- Results posted
- No
- Last update
- 31 March 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- Builds on itImpact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer. DOI 10.1002/iid3.70545↗
- Builds on itPhase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with r… DOI 10.1016/j.ejca.2022.11.035↗